Cheung, Alfred K; Chang, Tara I; Cushman, William C; Furth, Susan L; Ix, Joachim H; Peocits-Filho, Roberto; Perkovic, Vlado; Sarnak, Mark J; Tobe, Sheldon W; Tomson, Charles RV; +43 more... Cheung, Michael; Wheeler, David C; Winkelmayer, Wolfgang C; Mann, Johannes FE; Bakris, George L; Damasceno, Albertino; Dwyer, Jamie P; Fried, Linda F; Haynes, Richard; Hirawa, Nobuhito; Holdaas, Hallvard; Ibrahim, Hassan N; Ingelfinger, Julie R; Iseki, Kunitoshi; Khwaja, Arif; Kimmel, Paul L; Kovesdy, Csaba P; Ku, Elaine; Lerma, Edgar V; Luft, Friedrich C; Lv, Jicheng; McFadden, Christopher B; Muntner, Paul; Myers, Martin G; Navaneethan, Sankar D; Parati, Gianfranco; Peixoto, Aldo J; Prasad, Ramesh; Rahman, Mahboob; Rocco, Michael V; Rodrigues, Cibele Isaac Saad; Roger, Simon D; Stergiou, George S; Tomlinson, Laurie A; Tonelli, Marcello; Toto, Robert D; Tsukamoto, Yusuke; Walker, Robert; Wang, Angela Yee-Moon; Wang, Jiguang; Warady, Bradley A; Whelton, Paul K; Williamson, Jeff D; (2019) Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 95 (5). pp. 1027-1036. ISSN 0085-2538 DOI: https://doi.org/10.1016/j.kint.2018.12.025

Downloaded from: http://researchonline.lshtm.ac.uk/4652926/

DOI: https://doi.org/10.1016/j.kint.2018.12.025

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Alfred K. Cheung1, Tara I. Chang2, William C. Cushman3, Susan L. Furth4, Joachim H. Ix5,6,7, Roberto Pecoits-Filho8, Vlado Perkovic9,10, Mark J. Sarnak11, Sheldon W. Tobe12,13, Charles R.V. Tomson14, Michael Cheung15, David C. Wheeler16, Wolfgang C. Winkelmayer17 and Johannes F.E. Mann18,19; for Conference Participants20

In September 2017, KDIGO (Kidney Disease: Improving Global Outcomes) convened a Controversies Conference titled Blood Pressure in Chronic Kidney Disease (CKD). The purpose of the meeting was to consider which recommendations from the 2012 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD should be reevaluated based on new evidence from clinical trials. Participants included a multidisciplinary panel of clinical and scientific experts. Discussions focused on the optimal means for measuring blood pressure (BP) as well as managing BP in CKD patients. Consistent with the 2012 Guideline, the conference did not address BP management in patients on maintenance dialysis.

In patients with chronic kidney disease (CKD), the optimal blood pressure (BP) for minimizing the risk of CKD progression and systemic complications, particularly cardiovascular events, is unclear. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a clinical practice guideline on the management of BP in nondialysis CKD.1 Since then, new data from clinical trials, such as SPRINT (Systolic Blood Pressure Intervention Trial),2 HALT-PKD (Halt Progression of Polycystic Kidney Disease),3 and SPS3 (Secondary Prevention of Small Subcortical Strokes),4 have expanded the evidence base. To examine how the new evidence may influence guideline updates, KDIGO convened a multidisciplinary Controversies Conference titled Blood Pressure in CKD in Edinburgh, Scotland in September 2017. Here, we summarize the points of consensus and controversy and identify knowledge gaps and research priorities. The conference agenda, discussion questions, and plenary session presentations are available at http://kdigo.org/conferences/controversies-conference-on-blood-pressure.

BLOOD PRESSURE MEASUREMENT

A major emphasis during the conference was on BP measurement methods. BP can differ widely depending on measurement setting (e.g., office or home) and the type of device used (e.g., manual or oscillometric sphygmomanometer).5,6 Proper preparation prior to BP measurement is important (Table 1). Conference discussions focused primarily on the following 3 types of office-based BP measurements: (i) routine, or casual, office, which is conducted without following the recommended preparatory processes outlined in Table 1; (ii) standardized office,
which adheres to these processes but is performed with a manual technique; and (iii) automated oscillometric office, which includes a 5-minute rest followed by a series of 2 to 3 BP measurements that are averaged, as described, for example, in the SPRINT protocol. Two types of out-of-office BP measurements were discussed: (i) home automated oscillometric, and (ii) 24-hour ambulatory. Pulse wave velocity and central arterial BP were discussed: (i) home automated oscillometric, whereas standardized office BP measurements were felt to be outside the scope of the conference. Non-cuff-based BP measurements are not sufficiently validated to guide practice and were not discussed.

**Comparisons of different types of BP measurements**

Casual office BP is generally 5–10 mm Hg higher than both standardized office and automated oscillometric office BP, whereas standardized office BP measurements are generally similar to those of automated oscillometric office BP. Casual office BP is often higher than awake ambulatory BP; in contrast, standardized office BP may be lower than awake ambulatory BP. In a subset of participants in the intensive treatment arm of the SPRINT study, mean automated office systolic blood pressure (SBP) was 119 mm Hg, whereas mean awake ambulatory SBP was 126 mm Hg. The differences in BP obtained using different types of measurements in CKD appear similar to those in the general population, but the available data are limited. The differences between methods as discussed are population means; in the individuals, those differences may vary drastically. Therefore, establishing conversion factors to translate a casual BP value into a standardized BP value is difficult.

**Out-of-office BP measurements**

Out-of-office BP measurement is required to diagnose white-coat hypertension (elevated office BP with controlled out-of-office BP) and masked hypertension (controlled office BP with elevated out-of-office BP; Figure 1). The prevalence of white-coat hypertension in patients with CKD from several countries ranges from 2% to 41%, and the prevalence of masked hypertension ranges from 6% to 51%. Ambulatory BP provides important information on nocturnal BP. Patients with CKD are more likely to have an absence or even a reversal of normal nocturnal dipping, with prevalence ranging from 14% to 75% which appears to increase with decreasing kidney function.

In CKD, out-of-office BP may better predict kidney disease progression and cardiovascular events than office BP. Nocturnal BP can be treated specifically but whether this strategy improves clinical outcomes is unclear. In an 8-week, uncontrolled study of 32 nondipping patients with CKD, shifting 1 antihypertensive drug from morning to evening restored normal nocturnal dipping in 88% of patients. However, this study has yet to be replicated in a larger cohort with longer follow-up.

No adequately-powered randomized controlled trials (RCTs) of BP control on clinical outcomes have targeted ambulatory or home BP in the CKD or general adult population. The sample size needed and the complexity of such a trial raises questions about its feasibility. In addition, in many regions of the world, home BP or ambulatory BP monitoring are impractical.

**Other BP variabilities**

Orthostatic hypotension is usually defined as a decrease in SBP of at least 20 mm Hg or a decrease in diastolic BP (DBP) of at least 10 mm Hg within 3 minutes of standing up. Orthostatic hypotension is usually defined as a rise in SBP of at least 20 mm Hg when standing. Estimates based on SPRINT study data indicate that among older, hypertensive patients, 5% have orthostatic hypotension and 5% have orthostatic hypertension. Both groups carry an increased risk of cardiovascular events, as evidenced by multiple cohort studies.
BP can vary in the short term (minute-to-minute), medium term (day-to-day), or longer term (visit-to-visit variability, VVV). More advanced CKD is associated with higher VVV of SBP, and higher VVV in CKD is associated with adverse cardiovascular outcomes, adverse renal outcomes, and death. In a study of 114,900 patients with CKD, higher VVV of SBP, independent of absolute levels of SBP, was associated with higher rates of heart failure, hemorrhagic stroke, and death. Despite the prognostic information provided by VVV of SBP, conference participants felt that its use in the clinical setting or as a target of therapy remains unclear.

Conclusions and ongoing controversies in BP measurement

Conference participants suggested that the future guideline work group should explicitly state which BP measurements should be used to diagnose and manage BP in CKD. Standardized office BP measurement is rarely performed in clinical practice. Given that casual BP tends to provide higher values than other techniques, but more standardized techniques are often used in RCTs targeting BP, conference participants urged the future guideline work group to consider whether office BP should be measured using an automated oscillometric device with the appropriate preparations, as outlined in Table 1.

Conference participants also encouraged exploration of the evidence on out-of-office BP measurements in conjunction with office BP measurements in an updated guideline. More data are also needed regarding whether abnormal diurnal BP patterns can be restored in patients with CKD, and whether this strategy would improve clinical outcomes.

MANAGING BLOOD PRESSURE IN CKD PATIENTS WITH AND WITHOUT DIABETES

Salt intake

Lifestyle, including diet, is an integral component of BP management. Conference participants indicated that Recommendation 2.3.2 on salt intake (Chapter 2 of the 2012 KDIGO BP Guideline) should be reviewed to identify new evidence specific to people with CKD, as debate about optimal salt intake in the general population is ongoing. The conference participants questioned whether a level 1C recommendation is too strong based on the current evidence.

Therapeutic thresholds and targets of BP

In light of new research findings, especially from SPRINT, each recommendation in the 2012 BP guideline regarding BP diagnosis thresholds and treatment targets should be considered for revision. Whether separate recommendations are needed for diabetes mellitus and non-diabetes mellitus, and for different levels of albuminuria, depends in large part on where the threshold is set for lower-risk patients. For example, if the threshold is SBP <120 mm Hg for all patients, separate recommendations for higher-risk individuals would not be needed.

The extent to which SPRINT findings can and should be applied to persons with CKD G3b-G4 was debated.
Changes in indicators of kidney function in patients receiving BP-lowering therapies

Albuminuria. Meta-analysis of data from clinical trials has suggested that albuminuria is a valid surrogate endpoint for end-stage kidney disease (ESKD) for certain types of kidney disease. Conference participants agreed, however, that whether maximizing therapy to reduce albuminuria in addition to BP control, especially using agents that block the renin-angiotensin-aldosterone system (RAAS), is safe or effective in improving clinical outcomes is still unknown. The 2012 KDIGO BP Guideline also proposed a lower BP target and the use of RAAS inhibitors for people with albuminuria or proteinuria. Reassessment of these recommendations should be undertaken.

GFR. Conference participants debated whether the increased risk for acute declines in eGFR associated with lower BP goals in ACCORD, SPS3, and SPRINT is clinically important. A retrospective analysis of participants in the African American Study of Kidney Disease and Hypertension (AASK) and Modification of Diet in Renal Disease (MDRD) studies has indicated that patients who had acute eGFR declines ≥20% from baseline during intensive BP lowering were at increased risk of progression to ESKD. On the other hand, acute declines of up to 30% in eGFR upon the initiation of RAAS inhibitors were deemed by some investigators to portend long-term renal benefit. The conference participants felt that statistical methodological issues complicate the interpretation of such data. Critical review of the literature and the statistical methodologies used in various studies are necessary to determine if recommendations can be formulated. Analyses from BP-lowering trials using active run-in periods where changes in eGFR can be assessed pre-randomization instead of post-randomization would be particularly helpful in resolving this controversy.

Apart from the acute change in GFR upon BP lowering, several recent BP outcome trials, such as ACCORD, SPRINT, and SPS3, have also demonstrated that GFR loss is slightly but consistently faster during chronic follow-up with a lower BP target. These observations need to be carefully considered in the revised BP guideline.

Choice of antihypertensive agents

The conference participants agreed that an angiotensin-converting-enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) should be the agent of first choice among patients with severely increased albuminuria (i.e., >300 mg/g [>30 mg/mmol]) while some favor the preferential use of an ACEi or ARB for all CKD patients with diabetes and hypertension. The evidence favoring their preferential use for nondiabetic patients with CKD and moderately increased albuminuria (i.e., <300 mg/g [<30 mg/mmol]) is less persuasive. The relative benefits of these agents compared with alternatives also depend on ethnic origin and the healthcare setting (given the need to monitor for hyperkalemia).

Hyperkalemia

RAAS blockers inhibit renal potassium excretion and therefore increase the risk of hyperkalemia, particularly in patients with CKD, hence limiting their utilization despite their proven benefits. In a large retrospective analysis from the Veterans Health Administration database, CKD and RAAS inhibitor prescriptions were the strongest predictors of hyperkalemia. Several studies have shown a U-shaped relationship between serum potassium level and risk of death, although the risks may be lower if patients are under the active care of a nephrologist. The odds ratio of death from severe hyperkalemia (potassium >6.0 mmol/l) within 1 day of a measurement of serum potassium was very large, amounting to 31.6 for those without CKD, 19.5 for those with CKD G3, 11.6 for those with CKD G4, and 8.0 for those with CKD G5, suggesting the possibility of some degree of systemic adaptation to hyperkalemia with kidney impairment. However, the absolute risks of death associated with hyperkalemia over an 18-month period were higher among those with CKD, heart failure, and diabetes. In a cohort of patients managed by nephrologists, however, hypokalemia was associated with even higher risks of death than hyperkalemia.

Novel potassium-binding drugs, such as patiromer and sodium zirconium cyclosilicate, could potentially change the pharmacotherapy for hypertension, but conference participants felt it was too early to evaluate the role of these drugs in routine clinical practice. Further research is needed to examine whether potassium binders allow better treatment of hypertension, for example, using RAAS blockers, and thus reduce cardiovascular and renal complications (Table 2).

Dual inhibition of the renin-angiotensin system

Post hoc analyses from the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) and data from the Alikiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE) and the Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) trials suggested that dual therapy with an ACEi, an ARB, and/or a direct renin inhibitor did not provide cardiovascular or kidney benefit compared with monotherapy in patients with low eGFR and elevated albuminuria, although BP was somewhat lower. Additionally, the risks of hyperkalemia, acute kidney injury, and hypotension were greater with dual regimens.

In 2014, the European Medicines Agency endorsed restrictions on combining different classes of RAAS inhibitors in patients with diabetic nephropathy. A more recent meta-analysis suggested that dual ACEi and ARB treatments have efficacy in preventing ESKD in adults with diabetic kidney disease, if the treatments can be implemented safely. Conference participants discussed the possibility that dual RAAS regimens have long-term benefits in specific subgroups of patients, particularly those with a substantially lower degree of albuminuria while they are on dual versus monotherapy of RAAS inhibitors or when dual blockers are used in combination with potassium binders. Combining an ACEi or ARB with mineralocorticoid receptor antagonist may also confer additional protection, but the absence of informative RCTs means that we cannot currently assess the relative risks (including acute kidney injury and hyperkalemia) and benefits.
This controversial area calls for RCTs to be studied in specific patient groups.

**Resistant hypertension**

Resistant hypertension is common in CKD. The conference participants discussed the possible role of mineralocorticoid receptor antagonists (e.g., spironolactone, epleronone) in the treatment of resistant hypertension (by extension from studies in the general population) and as add-on anti-proteinuric treatment, with or without the concomitant use of novel potassium-binding drugs. However, participants concluded that evidence is insufficient to define the role of these agents in practice for those with CKD.

**MANAGING BLOOD PRESSURE IN OLDER PATIENTS WITH CKD**

The 2012 KDIGO BP guideline assigned a chapter to older patients and noted that very little evidence is available to guide management in nondiabetic older patients with CKD. Conference participants agreed that, although the term “older patients” has no universal definition, treatment decisions should carefully take into account age, comorbidities, and other concomitant therapies, and that dose escalation of antihypertensive agents should be gradual, with close attention to adverse events. The BP treatment target for older patients with advanced CKD is particularly controversial. Given the increasing incidence of ESKD in the older hypertensive population, study of the effects of antihypertensive therapy on cardiovascular and renal outcomes in older patients with advanced CKD remains an unmet need.

**Initiating antihypertensive therapy and treatment targets in older patients with CKD**

Conference participants recognized that for nonambulatory or nursing-home patient populations with CKD, no clinical trial data are available to inform decisions about antihypertensive therapy. Given that the aggregate benefits of antihypertensive therapy do not appear until 1–2 years after initiation of treatment, decisions regarding initiation of BP therapy and goals of treatment in persons with otherwise limited life expectancy should be based on shared decision-making with patients, family members, and caregivers, taking other medical and social conditions into consideration.

Based on available data, conference participants discussed whether the target for SBP should vary by age in adult CKD patients. First, participants noted that most trials in the older population have targeted SBP instead of DBP, since SBP better predicts cardiovascular disease, and isolated diastolic hypertension is rare in older adults. The SPRINT trial did not capture the whole spectrum of CKD patients, as patients with diabetes mellitus, eGFR <20 ml/min per 1.73 m², or proteinuria >1 g/d were excluded. Nonetheless, results from the SPRINT study suggest that cardiovascular and survival benefits are provided by an SBP target of <120 mm Hg (measured by automated oscillometric office BP) in the CKD population, including in those over 75 years old. Intensive SBP lowering did not impair gait speed or self-reported mobility. Less clear is whether older CKD patients with SBPs between 120 and 130 mm Hg (by standardized, not casual, BP measurement) should initiate treatment. A systematic review and perhaps future trials were suggested to provide insight into this issue. At the same time, such a systematic review should summarize methods of BP measurement in outcome trials.

Older patients commonly have CKD G3a without significant albuminuria. Conference participants questioned whether the degree of albuminuria should influence BP targets in this population for renoprotective effects, as discussed above. Cardiovascular risk reduction should be a priority in this group, but no evidence to date suggests that the cardiovascular-protective effects of lowering BP depend on the degree of albuminuria.

**Choice of antihypertensive agents in older patients with CKD**

The use of ACEis, ARBs, diuretics, and calcium channel blockers has been shown to be associated with improved cardiovascular outcomes in CKD patients. The 2012 KDIGO BP Guideline recommended that, if the degree of albuminuria is higher than 300 mg/g, ACEis or ARBs be included in the antihypertensive regimen because of their renoprotective effects. In a subgroup analysis of an RCT in older hypertensive patients, cardiovascular events were more frequent with single high-dose ARB therapy, compared with combination therapies using an ARB plus a calcium channel...
blocker.\textsuperscript{90} Although the number of events was quite small, conference participants suggested that this study be considered in the guideline update.

**Treatment monitoring in older patients with CKD**

With antihypertensive therapy, the concern is that older patients are likely to have a higher incidence of serious adverse events than younger patients. However, among those aged 75 years or older, targeting SBP \(< 120 \text{ mm Hg}\) did not cause more serious adverse events than targeting SBP \(< 140 \text{ mm Hg}\) in the entire cohort\textsuperscript{68} or in the CKD subgroup\textsuperscript{69} in SPRINT. Nonetheless, BP management in older individuals with CKD should be individualized, taking into account comorbidities, polypharmacy, and other factors.\textsuperscript{1}

**MANAGING BP AMONG INDIVIDUALS WITH CKD AND PREVIOUS STROKE**

This population is not specifically mentioned in the 2012 KDIGO BP guideline. The risk of stroke increases additively with declining GFR and increasing albuminuria, particularly in patients with an eGFR below 60 ml/min per 1.73 m\(^2\).\textsuperscript{91} and lowering BP generally reduces the risk for stroke and other cardiovascular events.\textsuperscript{92} Currently, no evidence suggests that a history of prior stroke should change the chronic treatment of BP in patients with CKD, as shown in a subgroup analysis of the Perindopril Protection against Recurrent Stroke Study (PROGRESS),\textsuperscript{93} although data are limited. In SPRINT, a history of stroke was an exclusion criterion. The SPS3 study\textsuperscript{94} targeted SBP treatment to \(< 130 \text{ mm Hg}\) in patients with a history of prior stroke and included 474 patients with baseline eGFR \(< 60 \text{ ml/min per 1.73 m}^2\). Compared with an SBP target of 130–149 mm Hg, a statistically nonsignificant reduction in the cardiovascular composite outcome occurred in the intensive SBP arm, with no effect modification by the baseline eGFR. Because of the paucity of data in this area, it is hoped that future RCTs of BP targets in people with prior stroke will include substantial numbers of individuals with CKD.\textsuperscript{95} Systematic reviews, meta-analyses, and perhaps additional data from RCTs are needed to inform the best practices for managing BP in CKD patients acutely and chronically after a stroke. At present, formulating recommendations for this group of patients would be difficult.

**MANAGING BP IN KIDNEY TRANSPLANT POPULATIONS**

**Treatment thresholds and targets in transplant recipients**

The KDIGO 2012 BP guideline suggested that adult kidney transplant recipients who have an office SBP consistently \(\geq 130 \text{ mm Hg}\) or a DBP consistently \(\geq 80 \text{ mm Hg}\) be treated to maintain SBP \(< 130 \text{ mm Hg}\) and DBP \(< 80 \text{ mm Hg}\), irrespective of the level of albuminuria,\textsuperscript{1} largely because the work group believed that adult transplant recipients are at high risk for both graft loss and development of cardiovascular disease. Since 2012, evidence published from a post hoc analysis in the FAVORIT (Folic Acid for Vascular Outcome Reduction in Transplantation) Trial showed that SBP increases were associated with increased risk for cardiovascular disease in kidney transplant recipients.\textsuperscript{96} This study did not address BP thresholds related to allograft failure. An important point to note is that BP was not a randomized intervention in FAVORIT. An earlier analysis of the Collaborative Transplant Study\textsuperscript{97} demonstrated a close association of SBP and chronic allograft failure in a monotonic manner in the range of SBP down to 140 mm Hg and DBP down to 90 mm Hg. No RCTs have been conducted that could inform the optimal target BP with regard to cardiovascular or renal allograft outcomes in kidney transplant recipients.

A key issue is whether evidence regarding management of BP in nontransplant CKD patients can be extrapolated to transplant recipients. Conference participants felt that such extrapolation should be tempered because transplanted kidneys are denervated and therefore may not autoregulate glomerular perfusion in the same manner as nontransplanted kidneys. Further, kidney transplant recipients are at risk of transplant renal artery stenosis, and they are frequently prescribed calcineurin inhibitors, which raise BP and influence renal perfusion. Based on clinical experiences, concerns were expressed regarding targeting SBP to \(< 120 \text{ mm Hg}\) in transplant recipients. Adequately powered outcome trials in kidney transplant patients, with a design similar to that of SPRINT, are needed, but obtaining the required financial resources for such a trial will be challenging.

**Choice of antihypertensive agents in transplant recipients**

The 2012 KDIGO BP guideline did not specify preferred choices of antihypertensive agents.\textsuperscript{1} Since 2012, reports have compared antihypertensive drugs in kidney transplant recipients. A 2016 meta-analysis by Hiremath et al.\textsuperscript{98} suggested that ACEIs or ARBs did not alter all-cause mortality or kidney outcomes but did increase the risk for hyperkalemia. Because of the small number of events and relatively short follow-up durations, the results of the meta-analysis were inconclusive.

In a randomized crossover trial of chlorthalidone versus amloidipine among kidney transplant patients treated with tacrolimus, patients in both arms experienced similar reductions in ambulatory SBP after 8 weeks.\textsuperscript{99} Chlorthalidone reduced proteinuria by 30% but also temporarily reduced kidney function. In an RCT of 153 kidney transplant recipients, participants were randomized to losartan versus matched placebo for up to 5 years. Both arms had their BP treated to a goal of \(< 130/80 \text{ mm Hg}\) using other agents. Randomization to losartan did not have a significant influence on the time to a composite of ESKD, death, or doubling of creatinine level.\textsuperscript{100}

Conference participants felt that this new evidence should be considered in the guideline update. The existing Recommendation 5.2 suggesting that choice of antihypertensive therapy take into account the time after transplantation, use of calcineurin inhibitors, presence or absence of albuminuria, and other comorbid conditions remains appropriate.

**Living kidney donors**

Living kidney donors were not specifically mentioned in the 2012 KDIGO BP guideline. In these individuals, each year of
age is associated with 9% greater odds of high BP requiring medication.\textsuperscript{101} The KDIGO 2017 clinical practice guideline on living kidney donors suggests that donor candidates be informed that donation may accelerate a rise in BP and that they should have BP measured every year postdonation.\textsuperscript{102} Conference participants agreed that although data linking close monitoring to improved clinical outcomes are not available, these recommendations are appropriate.

**MANAGING BP IN PEDIATRIC CKD POPULATIONS**

**Thresholds for initiating treatment**

Clinical trials assessing the effects of different BP targets on hard clinical endpoints in children who have CKD are limited. Applying BP guidelines in adults who have CKD to children who have CKD is not advisable because the normative BP values in children are dependent on age, gender, and height.

For the general pediatric population, the threshold for initiation of antihypertensive therapy has been the 95th percentile of normative BP values in the general pediatric population. Since the prior KDIGO CKD BP guideline was published, however, recognition of the effects of obesity on BP in children in general has increased. Thus, the American Academy of Pediatrics (AAP) guideline recently revised normative pediatric BP tables based on normal-weight children.\textsuperscript{103} The AAP further recommends that children and adolescents with CKD be evaluated for hypertension using automated oscillometric equipment to measure BP in an office-based setting.\textsuperscript{103} However, published normative BP values in children so far refer only to office auscultatory measurements. More normative data in children are needed for office-based and home-based automated oscillometric BP and ambulatory BP. Some normative data are available for ambulatory BP, but only in Western European populations.\textsuperscript{104}

Recommendation 6.1 in the 2012 KDIGO BP guideline suggested that for children with CKD, treatment should be started when BP is consistently above the 90th percentile for a child’s age, sex, and height.\textsuperscript{1} This recommendation is consistent with guidance from Hypertension Canada\textsuperscript{103} but at odds with that of the AAP\textsuperscript{103} and the European Society of Hypertension,\textsuperscript{106} which recommend that treatment be initiated if BP is consistently above the 95th percentile in the general pediatric population. A point to note is that these 3 guidelines are not specific to CKD patients. The AAP 2017 also recommends initiating treatment if BP is $>130/80$ mm Hg for children ages 13 years and above.\textsuperscript{105} However, the cutoff age of 13 years in CKD patients was considered potentially problematic by conference participants because many pediatric patients with CKD have small stature and may have a lower BP than is typical for their age. The 2012 KDIGO BP guideline for pediatric CKD patients should be reconsidered in light of these new AAP normative data and other guidelines.

**Treatment targets**

Recommendation 6.2 in the 2012 KDIGO BP guideline suggests that SBP and DBP be lowered to values $\leq$50th percentile in children with CKD, particularly in those with proteinuria.\textsuperscript{1} This recommendation was based primarily on the Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients (ESCAPE) trial, in which hypertensive pediatric CKD patients randomized to a mean arterial BP target of $<50$th percentile of normative values based on ambulatory BP measurements had fewer renal events than those randomized to the 50th–95th percentile.\textsuperscript{107} Yet, the KDIGO recommendation has applied these targets to SBP and DBP measured using the auscultatory method. Therefore, conference participants felt that the 2012 KDIGO guideline should be revised accordingly. On the other hand, the fact that ambulatory BP monitoring may not be widely available was noted; therefore, guidance also should provide a target clinic BP using automated oscillometric devices as an alternative. Provision of this guidance would require new normative data on automated oscillometric office-based BP readings that correspond to specific ambulatory BP levels for any given age, sex, and height. Development of such data was felt to be an important research recommendation.

**Choice of antihypertensive agent**

The 2012 KDIGO guideline Recommendation 6.3 suggests that an ARB or ACEi be used in children with CKD in whom treatment with BP-lowering drugs is indicated, irrespective of the level of proteinuria.\textsuperscript{1} This recommendation was based largely on preclinical data and data from adult studies. Only 4 small uncontrolled trials have shown that ACEis or ARBs reduce proteinuria in children with CKD.\textsuperscript{107} Evidence indicates that losartan\textsuperscript{108} and enalapril\textsuperscript{109} each lowers proteinuria in children, and that their effects are comparable,\textsuperscript{110} but data on end-organ consequences are unavailable. Conference participants also questioned whether the presence of proteinuria should be a consideration for the preferential use of ARBs or ACEis over other agents. Further research is needed on the long-term safety and efficacy of ARBs and ACEis in children with CKD.

**Pediatric kidney transplant recipients**

BP management in pediatric transplant recipients was considered to be an area without a sufficient evidence base to support guidelines. Additional research is warranted.

**CONCLUSION**

Overall, conference participants agreed that an update of the 2012 KDIGO BP guideline would be timely, particularly given the SPRINT data. In particular, BP thresholds and targets for treatment need to be reconsidered. Recommendations on where and how BP should be measured need to be emphasized. RCT data on the cardiovascular and survival benefits of diabetic kidney disease, advanced CKD, and severely increased proteinuric CKD are urgently needed for guidance regarding BP management in these CKD subgroups. Implementation of the updated guidelines was also recognized to be important, a process that
potentially can be facilitated by development of a patient decision aid for initiating antihypertensive treatment, with estimates of absolute risk and risk reduction from the treatment.

APPENDIX

Other conference participants

George L. Bakris, USA; Alberto Damasceno, Mozambique; Jamie P. Dwyer, USA; Linda F. Fried, USA; Richard Haynes, UK; Nobuhito Hirawa, Japan; Hallvard Holdaas, Norway; Hassan N. Ibrahim, USA; Julie R. Ingel, USA; Kunitoshi Iseki, Japan; Arif Khwaja, UK; Paul L. Kimmel, USA; Csaba P. Kovessy, USA; Elaine Ku, USA; Edgar V. Lemia, USA; Friedrich C. Luft, Germany; Jicheng Lv, China; Christopher B. McFadden, USA; Paul Muntner, USA; Martin G. Myers, Canada; Sankar D. Navaneethan, USA; Gianfranco Parati, Italy; Aldo J. Peixoto, USA; Ramesh Prasad, Canada; Mahboob Rahman, USA; Michael V. Rocco, USA; Cibele Isaac Saad Rodrigues, Brazil; Simon D. Roger, Australia; George S. Stergiou, Greece; Laurie A. Tomlinson, UK; Marcello Tonelli, Canada; Robert D. Toto, USA; Yusuke Tsukamoto, Japan; Robert Walker, New Zealand; Angela Yee-Moon Wang, Hong Kong; Jiguang Wang, China; Bradley A. Warady, USA; Paul K. Whelton, USA; Jeff D. Williamson, USA

DISCLOSURE

AKC declared having received consultancy fees from Boehringer Ingelheim and research support from the National Institutes of Health for SPRINT. TIC declared having received consultancy fees from Janssen Research and Development and Novo Nordisk; and research support from National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, and Satellite Healthcare. WCC declared having received consultancy fees from Sanofli; and research support from Eli Lilly and Company, National Institutes of Health, and National Institute on Aging. SLF declared having received research support from National Institutes of Health. JHI declared having received research support from Baxter Healthcare. RP-F declared having received consultancy fees from Akebia Therapeutics, AstraZeneca, Fresenius Medical Care, and Novo Nordisk; speaker honoraria from Akebia Therapeutics, AstraZeneca, and Novo Nordisk; and research support from Fresenius Medical Care. MJS declared having received research support from Akebia Therapeutics (monies paid to institution), National Institute of Diabetes and Digestive and Kidney Diseases, and National Institute on Aging. SWT declared having received research support from Abbott and Bayer HealthCare; speaker honoraria from Bausch, Pfizer, and Servier; and research support from KMH Labs. DCW declared having received consultancy fees from Akebia Therapeutics, Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen, and Vifor Fresenius; speaker honoraria from Amgen and Vifor Fresenius; and research support from AstraZeneca. WCW declared having received consultancy fees from Akebia Therapeutics, AMAG, Amgen, AstraZeneca, Bayer, Daichii-Sankyo, Relypsa, and ZS Pharma; speaker honoraria from FibroGen; and research support from National Institutes of Health. JFM declared having received consultancy fees from AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Celgene, Fresenius Medical Care, Novo Nordisk, and Vifor Pharma; speaker honoraria from B Braun, Eli Lilly and Company, Medice, Novo Nordisk, and Vifor Pharma; and research support from the European Union. All the other authors declared no competing interests.

ACKNOWLEDGMENTS

The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Akebia Therapeutics, Bayer HealthCare, Boehringer Ingelheim, Fresenius Medical Care, Pfizer, and Relypsa. We thank Jennifer King, PhD, for assistance with manuscript preparation.

REFERENCES


AK Cheung et al.: Blood pressure in kidney disease: A KDIGO conference report

KDIGO executive conclusions


KDIGO executive conclusions

AK Cheung et al.: Blood pressure in kidney disease: A KDIGO conference report


